公开(公告)号：US20160185876A1

公开(公告)日：2016-06-30

申请号：US14588212

申请日：2014-12-31

Applicant: Development Center for Biotechnology ,  DCB-USA LLC ,  National Health Research Institutes

Inventor： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Chao-Yang Huang ,  Ya-Wei Tsai ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Abstract translation: 人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

公开(公告)号：US20160068595A1

公开(公告)日：2016-03-10

申请号：US14785139

申请日：2014-04-18

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Chia-Cheng Wu ,  Chao-Yang Huang ,  Yu-Ying Lin ,  Yu-Jung Chen ,  Jiann-Shiun Lai

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: A humanized antibody, or a scFv, Fab, or F(ab′)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.

Abstract translation: 人源化抗体或其scFv，Fab或F（ab'）2包括：重链可变区或其同源变体，其中重链可变区包括：重链框架区，CDRH1具有 SEQ ID NO：19的序列，具有SEQ ID NO：20的序列的CDRH2和具有SEQ ID NO：21的序列的CDRH3，其中所述重链可变区和所述同源变体具有至少90％的序列同一性 在重链框架地区; 和轻链可变区或其同源变体，其包括：轻链框架区，具有SEQ ID NO：22的序列的CDRL1，具有SEQ ID NO：23的序列的CDRL2和具有SEQ ID NO：23的CDRL3，其具有 SEQ ID NO：24的序列，其中轻链可变区和同源变体在轻链框架区中共享至少90％的序列同一性。

公开(公告)号：US10781266B2

公开(公告)日：2020-09-22

申请号：US15924878

申请日：2018-03-19

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY ,  NATIONAL HEALTH RESEARCH INSTITUTES

Inventor： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Po-Yin Lin ,  Ya-Wei Tsai ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Hsien-Yu Tsai ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: A61K39/00 ,  C07K16/40 ,  A61P35/00 ,  G01N33/574

Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

公开(公告)号：US10947316B2

公开(公告)日：2021-03-16

申请号：US16010251

申请日：2018-06-15

Applicant: Development Center for Biotechnology

Inventor： Chao-Pin Lee ,  Shih-Hsien Chuang ,  Chuan-Lung Hsu ,  Yi-Jen Chen ,  Yu-Chin Nieh ,  Win-Yin Wei ,  Chia-Cheng Wu

IPC: A61P35/00 ,  A61K47/68 ,  A61K49/00 ,  G01N33/574 ,  A61K47/64 ,  A61K47/65 ,  A61K31/337 ,  A61K31/5365 ,  C07K16/30 ,  A61K39/395 ,  C07K16/28

Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab−(L−D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

公开(公告)号：US20200048365A1

公开(公告)日：2020-02-13

申请号：US15988875

申请日：2018-05-24

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

IPC: C07K16/34

Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

公开(公告)号：US20190330376A1

公开(公告)日：2019-10-31

申请号：US16475121

申请日：2017-12-29

Applicant: Development Center for Biotechnology

Inventor： Chen-Li Chien ,  Gregory Jiann Chen ,  Chuan-Lung Hsu ,  Jei-Hwa Yu ,  Hsien-Yu Tsai ,  Show-Shan Sheu ,  Wei-Jung Chang ,  Chia-Cheng Wu

IPC: C07K16/46 ,  C07K14/745

Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.

公开(公告)号：US20190106507A1

公开(公告)日：2019-04-11

申请号：US16010251

申请日：2018-06-15

Applicant: Development Center for Biotechnology

Inventor： Chao-Pin Lee ,  Shih-Hsien Chuang ,  Chuan-Lung Hsu ,  Yi-Jen Chen ,  Yu-Chin Nieh ,  Win-Yin Wei ,  Chia-Cheng Wu

IPC: C07K16/30 ,  A61P35/00 ,  A61K47/65 ,  A61K47/64 ,  A61K47/68

Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab−(L−D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

公开(公告)号：US10781265B2

公开(公告)日：2020-09-22

申请号：US15988875

申请日：2018-05-24

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

IPC: C07K16/34

Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

公开(公告)号：US09527922B2

公开(公告)日：2016-12-27

申请号：US14588212

申请日：2014-12-31

Applicant: Development Center for Biotechnology ,  DCB-USA LLC ,  National Health Research Institutes

Inventor： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Chao-Yang Huang ,  Ya-Wei Tsai ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: A61K39/395 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Abstract translation: 人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。